Sesquiterpene lactone specifically inhibiting activation of NF-κB by preventing the degradation of IκB-α and IκB-β. Also inhibits activation of MAP kinase (MAPK/ERK) and generation of leukotriene B4 and thromboxane B2.
PRODUCT PROPERTIES |
Alternative Name: | | (1aR-[1aR*,4E,7aS*,-10aS*,-10bR*])-2,3-6,7,7a,8,10a,10b-Octahydro-1a,5-dimethyl-8-methyleneoxireno[9,10]cyclo deca[1,2-b]furan-9(1aH)-one |
Formula: | | C15H20O3 |
MW: | | 248.32 |
Source: | | Isolated from feverfew leaves. |
CAS: | | 20554-84-1 |
MI: | | 13: 7120 |
RTECS: | | LY4220000 |
Purity: | | ≥98% |
Solubility: | | DMSO (100 mg/ml), Ethanol (20 mg/ml), Dichloromethane. |
Long Term Storage: | | +4°C |
Hazard: | | HARMFUL. |
|
|
|
Product Literature References
Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide: N.M. Patel, et al.; Oncogene
19, 4159 (2000),
Abstract;
Sesquiterpene lactones inhibit inducible nitric oxide synthase gene expression in cultured rat aortic smooth muscle cells: H.R. Wong & I.Y. Menendez; BBRC
262, 375 (1999),
Abstract;
The antiinflammatory sesquiterpene lactone parthenolide inhibits NF- kappa B by targeting the I kappa B kinase complex: S.P. Hehner, et al.; J. Immunol.
163, 5617 (1999),
Abstract;
Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta: S.P. Hehner, et al.; J. Biol. Chem.
273, 1288 (1998),
Abstract;
Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases: D. Hwang, et al.; BBRC
226, 810 (1996),
Abstract;
Feverfew extracts and parthenolide irreversibly inhibit vascular responses of the rabbit aorta: R.W. Barsby, et al.; J. Pharm. Pharmacol.
44, 737 (1992),
Abstract;
Inhibition of 5-lipoxygenase and cyclo-oxygenase in leukocytes by feverfew. Involvement of sesquiterpene lactones and other components: H. Sumner, et al.; Biochem. Pharmacol.
43, 2313 (1992),
Abstract;
A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro: W.A. Groenewegen & S. Heptinstall; J. Pharm. Pharmacol.
42, 553 (1990),
Abstract;